AKT1 and acute myeloid leukemia: Overall, hBM-MSC-induced Gal-3 overexpression in the AML cell line inhibits β-catenin degradation via overactivation of the PI3K/AKT pathway, which phosphorylates GSK-3β, thereby decreasing its activity.